Rare Disease Portfolio

About Recordati

Founded in 1926, Recordati has grown from a local Italian pharmacy into a global pharmaceutical force with a market valuation of approximately $9.9 billion. The company's strategy is built on a dual therapeutic focus—addressing widespread common diseases and high-need rare diseases—supported by a fully integrated value chain from R&D to manufacturing and global commercialization. With a presence in 150 countries, a robust pipeline, and a seasoned leadership team, Recordati is positioned for sustained growth as it celebrates its centennial and looks to the next century of innovation.

Therapeutic Areas